share_log

小鹏汽车三季度同比减亏超五成 金山软件三季度盈利增逾13倍|港股11月19日公告精选

Xiaopeng Autos' third-quarter losses decreased by more than 50% year-on-year, while Kingsoft's third-quarter profits increased by more than 13 times. Hong Kong stocks selected announcements on November 19.

cls.cn ·  Nov 19, 2024 21:34

① Xiaopeng Motor reduced its losses by more than 50% year on year in the third quarter. How was its revenue performance? ② Jinshan Software's profit increased more than 13 times in the third quarter. How big is the profit scale?

Financial Services Association, November 19 (Editor: Feng Yi) Financial Association brings you today's important announcements on Hong Kong stocks

1) Company news

Weibo-SW (09898.HK): Net revenue for the first three quarters was 1.298 billion US dollars, up 0.13% year on year; net profit was 0.292 billion US dollars, up 12.56% year on year.

Among them, net revenue for the third quarter was 0.464 billion US dollars, up 5.05% year on year; advertising and marketing revenue was 0.399 billion US dollars, up 2% year on year; net profit was 0.131 billion US dollars, up 68.5% year on year. As of September 2024, the number of monthly active users was 0.587 billion, and the average number of daily active users was 0.257 billion.

Xiaopeng Automobile-W (09868.HK): Total vehicle delivery volume in the third quarter was 46,533 vehicles, up 16.3% year on year; sales revenue was 8.8 billion yuan, up 12.1% year on year; gross profit margin was 8.6%, up 14.7 percentage points year on year; total revenue was 10.1 billion yuan, up 18.4% year on year; net loss was 1.81 billion yuan, down 53.5% year on year.

Tongcheng Travel (00780.HK): In the third quarter, transaction volume increased 2.4% year over year to 72.8 billion yuan; revenue was about 4.9915 billion yuan, up 51.3% year over year; net profit increased 55.8% year over year to about 0.803 billion yuan, average monthly paying users increased 5.0% year over year to 46.4 million, and annual paying users increased 3.4% year over year to 0.2324 billion yuan.

According to the announcement, the core online travel platform business achieved significant growth during the quarter. Revenue from transportation ticketing services increased 20.6% year over year to 2.0268 billion yuan, another record high.

Jinshan Software (03888.HK): Revenue for the third quarter was about 2.915 billion yuan, up 42% year on year, up 18% month on month; net profit was 0.413 billion yuan, up 13.51 times year on year, up 5% month on month. During the period, revenue from the office software and services business was approximately $1.207 billion, up 10% from the same period last year and 2% higher than the previous quarter. Revenue from online games and other businesses was 1.708 billion yuan, up 78% from the same period last year and 33% from the previous quarter.

Jinshan Cloud (03896.HK): Total revenue for the third quarter reached 1.886 billion yuan, a year-on-year increase of 16.0%. R&D expenditure was approximately 0.236 billion yuan, up 17.7% year over year. Non-GAAP EBITDA was approximately $0.185 billion, turning a year-on-year loss into a profit.

World Data - SW (09698.HK): Revenue for the third quarter was 2.966 billion yuan, up 17.7% year on year; net loss was 0.231 billion yuan, narrowing by 45.08% year on year; adjusted profit before interest and tax depreciation was 1.296 billion yuan, up 15% year on year.

According to the announcement, the company confirmed the guidelines previously provided. The total revenue for 2024 was 11.34 billion yuan to 11.76 billion yuan, and the adjusted profit before interest, tax and depreciation remained unchanged at 4.95 billion yuan to 5.15 billion yuan.

Fourth paradigm (06682.HK): Total revenue for the first three quarters was 3.218 billion yuan, up 26.1% year on year; gross profit was 1.35 billion yuan, up 12.5% year on year. The Prophet AI platform business achieved significant growth during the period. The revenue of the business reached 2.171 billion yuan, an increase of 50.2% over the previous year.

Junshi Biotech (01877.HK): Signed a license agreement involving two dual-target fusion proteins for the treatment of malignant tumors.

Skyworth Group (00751.HK): The subsidiary Skyworth Technology Consulting and Shenzhen Chuangxin Nanhua agreed to commit a total investment of 0.35 billion yuan to participate in the establishment of an investment fund.

According to the announcement, the fund's investment direction will focus on digital creative technology and equipment, digital cultural equipment, etc., including but not limited to next-generation ultra-high-definition professional display equipment, broadcast video equipment (including professional digital cameras, live video broadcasting vehicles for large-scale events, etc.), and advanced imaging systems.

Jingyou Pharmaceutical (00858.HK): Announces Yingxi. It is expected to have an interim profit of about HK$0.1 billion to HK$0.105 billion, turning a year-on-year loss into a profit.

Medical Thinking Health (02138.HK): Announced Yingxi, profit after tax is expected to increase by no less than 60% year-on-year in the medium term.

Novartis Health (06606.HK): Three products have been registered in accordance with the Hong Kong Medical Device Administration System.

Chinese Party Culture (01532.HK): The subsidiary plans to sell all of Zhejiang Zhongpai's shares for 80 million yuan.

2) Repurchase news

AIA (01299.HK): Repurchase 6.904 million shares at HK$0.396 billion at a repurchase price of HK$57.15-57.85.

CSPC Group (01093.HK): spent HK$29.5239 million to repurchase 5.73 million shares at a repurchase price of HK$5.12-5.21.

Swire Group A (00019.HK): spent HK$12.4465 million to repurchase 0.1905 million shares at a repurchase price of HK$64.4-65.8.

Alibaba-W (09988.HK): Spending $39.991 million to repurchase 3.5984 million shares at a repurchase price of $10.98-11.19.

Zheng Meiji (00564.HK): Shareholder Hong Yi invested to reduce its A-share holdings by 13.2097 million through centralized bidding transactions.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment